Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 6/20 | 0.39 |
| ▸ | NOS2 | P35228 | 3/20 | 0.39 |
| ▸ | NOS3 | P29474 | 2/20 | 0.39 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.34 |
| ▸ | NEK2 | P51955 | 1/20 | 0.34 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.34 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.34 |
| ▸ | BACE1 | P56817 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | NCF1 | P14598 | 2/20 | 0.33 |
| ▸ | NCK1 | P16333 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | MITF | O75030 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15650884 | 0.79 | NOS1 (0.54) | NOS1NOS2NOS3CLK4BACE1 | |
| SCHEMBL13209499 | 0.79 | NOS3 (0.38) | NOS1NOS2NOS3CHEK1NEK2 | |
| SCHEMBL995460 | 0.79 | NOS1 (0.34) | NOS1NOS2NOS3TP53KDM4E | |
| SCHEMBL31710095 | 0.77 | BACE1 (0.39) | NOS1NOS2NOS3BACE1TP53 | |
| SCHEMBL957352 | 0.76 | S100B (0.41) | NOS1NOS2NOS3BACE1KDM4E | |
| SCHEMBL18753138 | 0.74 | MCHR1 (0.46) | NOS1NOS2NOS3TP53KDM4E | |
| SCHEMBL2268818 | 0.74 | NNMT (0.37) | NOS1TP53KDM4ETSHRNPC1 | |
| SCHEMBL13209508 | 0.73 | — | — | |
| SCHEMBL13209498 | 0.71 | PIM1 (0.39) | KDM4ETSHRLMNAGAAHTT | |
| SCHEMBL31193319 | 0.70 | ADORA2B (0.42) | CLK4NPC1LMNARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110003866-A1 | NOVEL 2-DIMETHYLAMINO-3-AMIDO-6-AMINO-PYRIDINE DERIVATIVES USEFUL AS POTASSIUM CHANNEL ACTIVATORS | NEUROSEARCH A/S (DK) | 2011-01-06 | — | — | US | claimed |
| EP-2231610-A1 | NOVEL 2-DIMETHYLAMINO-3-AMIDO-6-AMINO-PYRIDINE DERIVATIVES USEFUL AS POTASSIUM CHANNEL ACTIVATORS | NeuroSearch A/S (DK) | 2010-09-29 | — | — | EP | claimed |
| WO-2009074591-A1 | NOVEL 2-DIMETHYLAMINO-3-AMIDO-6-AMINO-PYRIDINE DERIVATIVES USEFUL AS POTASSIUM CHANNEL ACTIVATORS | NEUROSEARCH A/S (DK) | 2009-06-18 | — | — | WO | claimed |
| US-20110003866-A1 | NOVEL 2-DIMETHYLAMINO-3-AMIDO-6-AMINO-PYRIDINE DERIVATIVES USEFUL AS POTASSIUM CHANNEL ACTIVATORS | NEUROSEARCH A/S (DK) | 2011-01-06 | — | — | US | disclosed |
| US-20110003866-A1 | NOVEL 2-DIMETHYLAMINO-3-AMIDO-6-AMINO-PYRIDINE DERIVATIVES USEFUL AS POTASSIUM CHANNEL ACTIVATORS | NEUROSEARCH A/S (DK) | 2011-01-06 | — | — | US | disclosed |
| EP-2231610-A1 | NOVEL 2-DIMETHYLAMINO-3-AMIDO-6-AMINO-PYRIDINE DERIVATIVES USEFUL AS POTASSIUM CHANNEL ACTIVATORS | NeuroSearch A/S (DK) | 2010-09-29 | — | — | EP | disclosed |
| EP-2231610-A1 | NOVEL 2-DIMETHYLAMINO-3-AMIDO-6-AMINO-PYRIDINE DERIVATIVES USEFUL AS POTASSIUM CHANNEL ACTIVATORS | NeuroSearch A/S (DK) | 2010-09-29 | — | — | EP | disclosed |
| WO-2009074591-A1 | NOVEL 2-DIMETHYLAMINO-3-AMIDO-6-AMINO-PYRIDINE DERIVATIVES USEFUL AS POTASSIUM CHANNEL ACTIVATORS | NEUROSEARCH A/S (DK) | 2009-06-18 | — | — | WO | disclosed |
| WO-2009074591-A1 | NOVEL 2-DIMETHYLAMINO-3-AMIDO-6-AMINO-PYRIDINE DERIVATIVES USEFUL AS POTASSIUM CHANNEL ACTIVATORS | NEUROSEARCH A/S (DK) | 2009-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003866-A1 | NOVEL 2-DIMETHYLAMINO-3-AMIDO-6-AMINO-PYRIDINE DERIVATIVES USEFUL AS POTASSIUM CHANNEL ACTIVATORS | KCNA7, KCNJ2, KCNN3 | NOS1 2771/4885NOS2 2594/4885NOS3 1881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.